USS Investment Management Ltd Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

USS Investment Management Ltd cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,366 shares of the biopharmaceutical company's stock after selling 6,505 shares during the period. USS Investment Management Ltd's holdings in Alnylam Pharmaceuticals were worth $6,210,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Allworth Financial LP grew its holdings in Alnylam Pharmaceuticals by 6.8% during the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 38 shares during the period. Investment Management Corp of Ontario boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares during the period. Nixon Peabody Trust Co. boosted its stake in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares during the period. Brevan Howard Capital Management LP boosted its holdings in shares of Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares during the period. Finally, IFP Advisors Inc lifted its holdings in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.1%

ALNY traded up $0.38 during trading on Tuesday, hitting $290.34. 490,089 shares of the company's stock were exchanged, compared to its average volume of 917,016. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $146.79 and a fifty-two week high of $304.39. The stock has a market cap of $37.86 billion, a P/E ratio of -133.95 and a beta of 0.17. The business's 50 day moving average is $259.09 and its two-hundred day moving average is $254.28. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the previous year, the firm posted ($0.16) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ALNY. Royal Bank of Canada lifted their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.